

David Kim

Counsel
Gemini Law LLP



 dkim@geminilaw.com

David Kim joined Gemini Law as Of Counsel in 2022. David is a USPTO registered patent attorney with over 10 years of experience handling IP litigation and strategy in the biopharma and AI sectors. David represents life science companies developing biopharma drugs, as well as biotech and AI companies pioneering the latest technology in the field of oncology. David has significant experience advising clients during the life cycle of drug development, providing pre-litigation strategy, and helping international clients bring biopharma drugs into the US market. David also helps AI medical device companies develop global business models and devise effective IP strategies for the AI SaMD.

LANGUAGE

- English
- Korean

BAR ADMISSIONS

- Texas
- U.S. Patent & Trademark

EDUCATION

- J.D., University of Oklahoma College of Law, 2012
- B.A., Comparative Literature, Cornell University, 2004
(background in Biochemistry and Engineering)

EXPERIENCE

Prior to joining Gemini Law, David was Senior Legal Counsel at Lunit, a medical AI company dedicated to conquering cancer through AI. He advised internal clients on various legal and IP issues pertaining to AI diagnostic software, AI-driven biomarkers, telehealth services, and new healthcare business models utilizing AI technology.

David was also Patent Litigation Counsel at Celltrion, a global biopharmaceutical company focused on the development and manufacture of biosimilars for global markets. There he advised the company on IP due diligence, freedom-to-operate, and implemented global patent litigation strategy for Celltrion as the first mover to introduce infliximab, rituximab, and trastuzumab biosimilar drugs to patients worldwide. As in-house counsel, David managed a number of BPCIA litigations, IPRs, EPO oppositions, PMNOC proceedings, and national-level invalidity actions, in addition to successfully defending preliminary injunctions and infringement actions. David has deep knowledge concerning the development, manufacture, regulatory approval, and commercialization of biologics.